Last reviewed 2026-04-21 · How we verify

Eutravac

LG Life Sciences · Phase 3 active Biologic Quality 0/100

Eutravac is a Biologic drug developed by LG Life Sciences. It is currently in Phase 3 development. Also known as: LG DTaP Vaccine Inj. (DTaP), Euvax B (Hepatitis B), Hepavax (Hepatitis B).

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Eutravac
Also known as	LG DTaP Vaccine Inj. (DTaP), Euvax B (Hepatitis B), Hepavax (Hepatitis B)
Sponsor	LG Life Sciences
Modality	Biologic
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eutravac CI brief — competitive landscape report
Eutravac updates RSS · CI watch RSS
LG Life Sciences portfolio CI

Frequently asked questions about Eutravac

What is Eutravac?

Eutravac is a Biologic drug developed by LG Life Sciences.

Who makes Eutravac?

Eutravac is developed by LG Life Sciences (see full LG Life Sciences pipeline at /company/lg-life-sciences).

Is Eutravac also known as anything else?

Eutravac is also known as LG DTaP Vaccine Inj. (DTaP), Euvax B (Hepatitis B), Hepavax (Hepatitis B).

What development phase is Eutravac in?

Eutravac is in Phase 3.

Manufacturer: LG Life Sciences — full pipeline
Therapeutic area: All drugs in Other
Also known as: LG DTaP Vaccine Inj. (DTaP), Euvax B (Hepatitis B), Hepavax (Hepatitis B)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing